AnGes,Inc. Global leader in gene Medical

Select Language



HGF Genetic Medicine development project HGF (Hepatocyte Growth Factor) was discovered in 1984 in Japan as a protein to help the growth of hepatocyte. Although research on HGF at first focused on the development of medicines for liver diseases, it was found that HGF has a novel function as an angiogenic growth factor that promotes the growth of blood vessels. The local delivery of DNA Plasmid encoding HGF developed a new method to regenerate blood vessels and has a high potential to become a curative medicine for ischemic patients who are suffering from deteriorating blood circulation due to clogged vessels.

Examples of diseases caused by the clogging of blood vessels include: critical limb ischemia (PAD, consisting of arteriosclerosis obliterans and Buerger's disease), that may ultimately lead to the amputation of a lower limb due to necrosis caused by poor blood circulation. For patients with severe ischemic conditions, the balloon-catheter treatment (therapy to form arteries by the insertion of a catheter into blood vessels) as well as bypass surgery are the currently applied solutions in addition to drug administration. These treatments, however, do not always ensure full recovery.

In March 2019, AnGes,Inc. acqured an application for marketing approval for HGF for critical limb ischemic in Japan. It is the first gene therapy medicine approved in Japan.

HGF Plasmid on Peripheral Arterial Diseases
Before genetic medicine
Before gene therapy

After genetic medicine
After gene therapy


  • News Release
  • About AnGes
  • Projects
  • For Investors
  • HomeSite mapPrivacy PolicySite PolicyContact
  • Copyright© AnGes, Inc. All Rights Reserved.